Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$2.17 USD
-0.06 (-2.69%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.18 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRVS 2.17 -0.06(-2.69%)
Will CRVS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVS
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
What Makes Corvus (CRVS) a New Buy Stock
Other News for CRVS
Corvus Pharmaceuticals Is Ready To Take Flight
The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
Fly Insider: Sensata, BioMarin among week's notable insider trades
Biotech Alert: Searches spiking for these stocks today